The little pill that could: one medicine taking on two neglected diseases
Since 1999 we have donated over ten billion albendazole tablets. This pill is part of the fight against not one – but two – neglected tropical diseases(NTDs) that burden some of the very poorest communities.
Bhagwati is a mother of five living in Nepal, where she and her family farm their land. She is warm-hearted and welcoming, but her wide smile belies years of pain and her long, colourful sari hides a familiar swelling of the leg.
Like the estimated 120 million people worldwide, Bhagwati suffers from lymphatic filariasis (LF) and more than 40 million are living with the pain and stigma of the debilitating swelling it causes. One of the world’s leading causes of disability, LF in its most severe form can lead to elephantiasis. As a result of the symptoms, sufferers are often isolated, unable to work and trapped in poverty.
The World Health Organization estimates that 893 million people in 49 countries are living in areas where LF is transmitted and are at risk of being infected.
Bhagwati first started to experience symptoms when she was pregnant with her eldest daughter. She suffered from fevers, aches and a pain in her leg – which was growing bigger by the year. Life got even tougher when several years later, Bhagwati lost her husband. My children were very small when my husband passed away,” said Bhagwati. “I struggled to raise them and send them to school. I have struggled very hard in life.”
But the experiences of Bhagwati and millions of other LF patients could become a thing of the past thanks to efforts to wipe out the disease. At the turn of the millennium, the World Health Organization launched its global programme to eliminate LF with the aim of defeating the disease as a global health problem by 2020.
Organisations from across the non-profit and private sector have got behind the WHO’s campaign, including GSK. For the past 20 years, the company has donated a medicine called albendazole to support the fight against LF. This small, white pill is used in combination with other medicines to help prevent transmission of the disease – which is spread by a parasite that mosquitoes carry. By December 2020, GSK had donated 10 billion albendazole tablets to the WHO to be used in 92 countries.
One medicine fighting two neglected tropical diseases
Not only is albendazole part of the fight against LF, but this pill is also taking on soil-transmitted helminths. These intestinal worms infect over 700 million children worldwide, particularly in poorer countries. They are spread through contaminated soil and can impair development and result in anaemia, lethargy, stunted growth and malnutrition
Because diseases like intestinal worms and LF affect lower income countries, they have not always had the investment they deserve – in terms of scaling up treatments and researching new medicines. But defeating these so-called ‘neglected tropical diseases’ could help strengthen the economic health of developing countries, as well as enhance the wellbeing of those who live there.
In 1999, GSK began donating albendazole tablets to the global effort to defeat LF. A decade later, GSK scaled up its efforts by dedicating a new production facility in India to making albendazole. And GSK remains committed to continuing to donate albendazole tablets until LF is eliminated as a public health issue.
17 countries have announced elimination of LF and researchers estimate the number of people at risk of infection of LF has almost halved.
You may also like
Fighting malaria in the lab and on the ground
Despite progress to fight malaria millions continue to suffer. At GSK, the biggest contribution we can make is through our science.
Preparing for future disease threats
We work to tackle some of the root causes of disease and contribute to healthier communities around the world